The use of nanosecond pulsed electric fields to ablate tumors (nanoelectroablation) is now well established in the murine xenograft model system. In order bring this therapy into the clinic for the treatment of human tumors we are developing both a pulse generator as well as delivery electrodes to target the tumors to be treated. We will describe the PulseCure® Model MBR-1 100 ns pulse generator and the first human clinical trial data using nanoelectroablation to scarlessly ablate basal cell carcinomas.
Conference Committee Involvement (1)
Terahertz and Ultrashort Electromagnetic Pulses for Biomedical Applications
2 February 2014 | San Francisco, California, United States